Hamlet BioPharma AB (publ)

NGM:HAMLET B Rapporto sulle azioni

Cap. di mercato: SEK 533.5m

Hamlet BioPharma Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Petter Lindqvist

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO1.1yrs
Proprietà del CEOn/a
Durata media del managementNessun dato
Durata media del Consiglio di amministrazioneNessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Jul 04
Is Hamlet Pharma (NGM:HAMLET B) In A Good Position To Invest In Growth?

Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

Mar 04
Here's Why We're Watching Hamlet Pharma's (NGM:HAMLET B) Cash Burn Situation

We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

Nov 10
We Think Hamlet Pharma (NGM:HAMLET B) Can Afford To Drive Business Growth

We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Jun 17
We Think Hamlet Pharma (NGM:HAMLET B) Can Easily Afford To Drive Business Growth

Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Oct 12
Companies Like Hamlet Pharma (NGM:HAMLET B) Are In A Position To Invest In Growth

Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

Mar 17
Will Hamlet Pharma (NGM:HAMLET B) Spend Its Cash Wisely?

AMMINISTRATORE DELEGATO

Petter Lindqvist

1.1yrs

Mandato

Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...